TASSETTI, LUIGI
 Distribuzione geografica
Continente #
NA - Nord America 269
EU - Europa 259
AS - Asia 134
Totale 662
Nazione #
US - Stati Uniti d'America 269
IT - Italia 74
IE - Irlanda 71
SE - Svezia 53
HK - Hong Kong 52
RU - Federazione Russa 39
CN - Cina 36
JO - Giordania 20
SG - Singapore 19
GB - Regno Unito 7
CH - Svizzera 6
DE - Germania 5
KR - Corea 4
IN - India 3
BE - Belgio 1
FI - Finlandia 1
NL - Olanda 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 662
Città #
Dublin 71
Chandler 44
Hong Kong 40
Fairfield 21
Florence 21
Altamura 18
Ashburn 18
Lawrence 18
New York 14
Singapore 14
Buffalo 12
Princeton 12
Boston 11
Moscow 11
Shanghai 11
Beijing 7
Bern 6
San Diego 6
Kent 5
Seattle 5
Woodbridge 5
Bologna 4
Cambridge 4
Los Angeles 4
Medford 4
Seoul 4
Hillsboro 3
Houston 3
Lecce 3
Wilmington 3
Campi Bisenzio 2
Cesano Boscone 2
Effeltrich 2
Kilburn 2
Lodi 2
Lurano 2
Munich 2
Redwood City 2
Reggio Emilia 2
Trinitapoli 2
Tukwila 2
Turin 2
Vellore 2
West Jordan 2
Ann Arbor 1
Arezzo 1
Boardman 1
Breendonk 1
Falls Church 1
Grosseto 1
Guangzhou 1
Hagen 1
Hangzhou 1
Helsinki 1
Košice 1
London 1
Nanjing 1
Naples 1
Norwalk 1
Pisa 1
Pontedera 1
Pune 1
Southwark 1
Sovizzo 1
Staranzano 1
Washington 1
Wuhan 1
Totale 453
Nome #
Emerging Medical Treatment for Hypertrophic Cardiomyopathy 57
Strength of clinical indication and therapeutic impact of the implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy 56
Stress echo 2030: The novel ABCDE-(FGLPR) protocol to define the future of imaging 55
Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives 53
Predicting Mortality Risk in Older Hospitalized Persons With COVID-19: A Comparison of the COVID-19 Mortality Risk Score with Frailty and Disability 48
Prevalence of Inherited Cardiac Diseases Among Young Patients Requiring Permanent Pacing 47
Factors associated with persistence of symptoms 1 year after COVID-19: A longitudinal, prospective phone-based interview follow-up cohort study 43
Early Diagnosis and Outcome in Patients With Wild-Type Transthyretin Cardiac Amyloidosis 41
Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study 38
Prognostic value of reduced heart rate reserve during exercise in hypertrophic cardiomyopathy 35
Relationship between hyponatremia at hospital admission and cardiopulmonary profile at follow-up in patients with SARS-CoV-2 (COVID-19) infection 34
Prevalence and prognostic role of nonsustained ventricular tachycardia in cardiac amyloidosis 32
Clinical course and outcome of pregnancy in patients with hypertrophic cardiomyopathy 32
Incidence of stroke in patients with hypertrophic cardiomyopathy in stable sinus rhythm during long-term monitoring 24
Prevalence and predictors of bradyarrhythmias requiring permanent pacing in patients with Anderson-Fabry disease 23
Sex-related differences in clinical presentation and all-cause mortality in patients with cardiac transthyretin amyloidosis and light chain amyloidosis 22
Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: Real-world experience in a National Referral Center 18
Incidence and determinants of atrial fibrillation in patients with wild-type transthyretin cardiac amyloidosis 14
Impact of Pregnancy on the Natural History of Women with Hypertrophic Cardiomyopathy 14
Totale 686
Categoria #
all - tutte 4.776
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.776


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20219 0 0 0 0 0 0 0 0 5 0 4 0
2021/2022109 15 0 3 0 0 6 0 6 16 9 22 32
2022/2023304 17 57 15 12 15 45 48 24 39 6 12 14
2023/2024207 4 17 19 12 11 31 17 50 6 16 13 11
2024/202557 37 20 0 0 0 0 0 0 0 0 0 0
Totale 686